GlobalData on MSN7d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with ...
Pharmaceutical Technology7d
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
Johnson & Johnson developed the dual-acting monoclonal antibody. Credit: Skorzewiak/Shutterstock. Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its ...
Benzinga.com7d
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
FDA approved Johnson & Johnson’s Tremfya as the first IL-23 inhibitor with both SC and IV induction options for Crohn’s disease. Tremfya sales reached $3.67 billion in 2024, marking a 17% year ...
Business Insider7d
FDA approves Johnson & Johnson’s TREMFYA in Crohn’s disease
The company states: “Johnson & Johnson announced that the FDA has approved TREMFYA, or guselkumab, the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options ...
Pharm Exec7d
FDA Approves Johnson & Johnson’s Tremfya for Crohn Disease
Tremfya is the first and only IL-23 inhibitor with both subcutaneous and intravenous induction options for adults with moderately to severely active Crohn disease in the United States. The FDA has ...
Investing10d
Johnson & Johnson’s nipocalimab gets FDA Fast Track for Sjögren’s disease
SPRING HOUSE, Pa. - Johnson & Johnson (NYSE: JNJ) has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for nipocalimab, intended for the treatment of adult patients ...
Business Insider10d
Johnson & Johnson says FDA grants Fast Track designation to nipocalimab
Johnson & Johnson announced that the U.S. FDA has granted investigational nipocalimab Fast Track designation for the treatment of adult patients with moderate-to-severe Sjogren’s disease, having ...